Cited by 466Glioma Diagnosis and TreatmentLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Haas-Kogan, Daphne A., Prados, Michael D., Tihan, Tarik, Eberhard, David A., Jelluma, Nannette, Arvold, Nils D., Baumber, Rachel, Lamborn, Kathleen R., Kapadia, Ami, Malec, Mary, Berger, Mitchel S., Stokoe, David·2005·JNCI Journal of the National Cancer Institute

DOI 10.1093/jnci/dji161

Open this paper in CoChat — free account

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent temozolomide. METHODS: Expression of EGFR and ligand-independent EGFRvIII mutant proteins and of phosphorylated protein kinase B (PKB)/Akt in specimens from glioma patients were assessed by immunohistochemistry. EGFR gene amplification was evaluated by fluorescence in situ hybridization. Mutations in PTEN and EGFR were assessed by polymerase chain reaction amplification and sequencing. Response was evaluated by sequential magnetic resonance imaging every 2 months. The Cochran-Mantel-Haenzel test was used to assess associations between biomarker status and response. All statistical tests were two-sided. RESULTS: Of 41 glioma patients, eight responded to treatment. Response to erlotinib was associated with EGFR expression (P = .07) and EGFR amplification (P = .08). These associations were stronger and statistically significant among the 29 patients initially diagnosed with glioblastoma multiforme (P = .03 and P = .02, respectively). Among six responders with sufficient tumor tissue, none had EGFRvIII mutations. None of the 22 tumors with high levels of phosphorylated PKB/Akt responded to erlotinib treatment, whereas eight of the 18 tumors with low levels of phosphorylated PKB/Akt responded to erlotinib treatment (P < .001). The level of phosphorylated PKB/Akt was also associated with time to progression (P < .001). CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

Integrity signals

Registry

Crossref · 10.1093/jnci/dji161

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695
EGFR and cancer prognosis.
Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J. M., & Baselga, J. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,257
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548

Show all 37 references

Research works printed but not linked: 2

Salz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc ASCO2001 (abstr); 20 : 7A .
Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc ASCO2002 (abstr); 21 : 504 .

Sorted by citations

Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L. J., Yedjou, C. G., Hsu, H.-Y., Lin, L., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 897
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C. E., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 859
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clément, P. M., Frénay, M., Campone, M., Baurain, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 587
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 558
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
Stupp, R., Hegi, M. E., Gilbert, M. R., & Chakravarti, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8554 · Cited by 531
Recent advances in the molecular understanding of glioblastoma
Bleeker, F. E., Molenaar, R. J., & Leenstra, S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0793-0 · Cited by 468
An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway
Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A. N., Soto, H., Zhu, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0102 · Cited by 452
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., González, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 460
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaïh, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 460
The EGFRvIII variant in glioblastoma multiforme
Gan, H. K., Kaye, A. H., & Luwor, R. B. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.12.005 · Cited by 407
Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Prados, M. D., Chang, S. M., Butowski, N. A., DeBoer, R. J., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J. R., Rabbitt, J. E., Page, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
The epidermal growth factor receptor variant III ( EGFR v III ): where wild things are altered
Gan, H. K., Cvrljevic, A. N., & Johns, T. G. (2013) · FEBS Journal · doi:10.1111/febs.12393 · Cited by 394
Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., & Cairncross, J. G. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 372
Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment
Hoelzinger, D. B., Demuth, T., & Berens, M. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm187 · Cited by 370
Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain
Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W., Debiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P. L., Yuza, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030485 · Cited by 378
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy
Guo, D., Prins, R. M., Dang, J., Kuga, D., Iwanami, A., Soto, H., Lin, K. Y., Huang, T. T., Akhavan, D., Hock, M. B., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000446 · Cited by 351
Glioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. A. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 354
Molecularly targeted therapy for malignant glioma
Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J., & Rich, J. N. (2007) · Cancer · doi:10.1002/cncr.22741 · Cited by 330
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Szopa, W., Burley, T. A., Krämer-Marek, G., & Kaspera, W. (2017) · BioMed Research International · doi:10.1155/2017/8013575 · Cited by 334
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
Pelloski, C. E., Ballman, K. V., Furth, A. F., Zhang, L., Lin, E., Sulman, E. P., Bhat, K., McDonald, J. M., Yung, W. K. A., Colman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0705 · Cited by 308
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 317
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 309
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 310
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K., Wen, P. Y., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 306
Nonsurgical Treatment of Recurrent Glioblastoma
Gallego, O. S. (2015) · Current Oncology · doi:10.3747/co.22.2436 · Cited by 296
Recent Advances in Therapy for Glioblastoma
Clarke, J. L., Butowski, N. A., & Chang, S. M. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.5 · Cited by 284
Molecular diagnostics of gliomas: state of the art
Riemenschneider, M. J., Jeuken, J. W. M., Wesseling, P., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0736-4 · Cited by 295
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
Jansen, M., Yip, S. S. F., & Louis, D. N. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70105-8 · Cited by 276
Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities
Itakura, H., Achrol, A. S., Mitchell, L. A., Loya, J. J., Liu, T. T., Westbroek, E. M., Feroze, A. H., Rodriguez, S., Echegaray, S., Azad, T. D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7582 · Cited by 270
EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma
Mukherjee, B., Mcellin, B. M., Camacho, C. V., Tomimatsu, N., Sirasanagandala, S., Nannepaga, S., Hatanpaa, K. J., Mickey, B., Madden, C. J., Maher, E. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4853 · Cited by 281
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 277
Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 262
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J., D'Hondt, L. A., Strauven, T., Chaskis, C., Veld, P. I. '., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 260
New insights into PTEN
Tamgüney, T., & Stokoe, D. (2007) · Journal of Cell Science · doi:10.1242/jcs.015230 · Cited by 230
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J. E., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 235
Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents
Reardon, D. A., & Wen, P. Y. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-152 · Cited by 233
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J. E., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 230
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Hasselbalch, B., Lassen, U., Hansen, S., Holmberg, M., Mau‐Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M., & Poulsen, H. S. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop063 · Cited by 229
Mouse Models of Brain Tumors and Their Applications in Preclinical Trials
Fomchenko, E. I., & Holland, E. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0438 · Cited by 223
Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
Garland, L. L., Rankin, C. J., Gandara, D. R., Rivkin, S. E., Scott, K., Nagle, R. B., Klein–Szanto, A. J., Testa, J. R., Altomare, D. A., & Borden, E. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7634 · Cited by 220
High incidence of EMMPRIN expression in human tumors
Riethdorf, S., Reimers, N., Assmann, V., Kornfeld, J., Terracciano, L., Sauter, G., & Pantel, K. (2006) · International Journal of Cancer · doi:10.1002/ijc.22062 · Cited by 219
Epidermal Growth Factor Receptor Expression Identifies Functionally and Molecularly Distinct Tumor-Initiating Cells in Human Glioblastoma Multiforme and Is Required for Gliomagenesis
Mazzoleni, S., Politi, L. S., Pala, M., Cominelli, M., Franzin, A., Sergi, L. S., Falini, A., Palma, M. D., Bulfone, A., Poliani, P. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2353 · Cited by 219
Posttranslational Protein Modifications
Krueger, K. E., & Srivastava, S. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r600009-mcp200 · Cited by 217
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Franceschi, E., Cavallo, G., Lonardi, S., Magrini, E., Tosoni, A., Grosso, D., Scopece, L., Blatt, V., Urbini, B., Pession, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603669 · Cited by 211
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods
Mountz, J. M., Ahmed, R., Oborski, M. J., Lieberman, F. S., & Hwang, M. (2014) · Cancer Management and Research · doi:10.2147/cmar.s54726 · Cited by 214
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Thiessen, B. A., Stewart, C. F., Tsao, M., Kamel‐Reid, S., Schaiquevich, P. S., Mason, W. P., Easaw, J. C., Bélanger, K., Forsyth, P. A., McIntosh, L., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1041-6 · Cited by 215
Genetically Engineered Mouse Models in Cancer Research
Walrath, J. C., Hawes, J. J., Dyke, T. V., & Reilly, K. M. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)06004-5 · Cited by 222
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
Sarkaria, J. N., Yang, L., Grogan, P. T., Kitange, G. J., Carlson, B. L., Schroeder, M. A., Galanis, E., Giannini, C., Wu, W., Dinca, E. B., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0691 · Cited by 197
Lessons learned in the development of targeted therapy for malignant gliomas
Omuro, A. M. P., Faivre, S. J., & Raymond, É. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0047 · Cited by 196
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Hegi, M. E., Diserens, A., Bady, P., Kamoshima, Y., Kouwenhoven, M. C. M., Delorenzi, M., Lambiv, W. L., Hamou, M., Matter, M. S., Koch, A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0048 · Cited by 195
A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN -Mutant Glioma
Fan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 192
Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
Uhm, J. H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J. C., Buckner, J. C., James, C. D., Scheithauer, B. W., Behrens, R. J., Flynn, P. J., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.070 · Cited by 191
Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Minniti, G. C., Muni, R., Lanzetta, G., Marchetti, P., & Enrici, R. M. (2009) · PubMed · Cited by 191
mTOR signaling in glioblastoma: lessons learned from bench to bedside
Akhavan, D., Cloughesy, T. F., & Mischel, P. S. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq052 · Cited by 195
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., Sathornsumetee, S., Herndon, J. E., Dowell, J. M., McLendon, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2215 · Cited by 190
EGFR as a clinical marker in glioblastomas and other gliomas
Saadeh, F. S., Mahfouz, R. A., & Assi, H. I. (2017) · The International Journal of Biological Markers · doi:10.5301/ijbm.5000301 · Cited by 190
EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma
Fan, Q., Cheng, C., Knight, Z. A., Haas-Kogan, D. A., Stokoe, D., James, C. D., McCormick, F. P., Shokat, K. M., & Weiss, W. A. (2009) · Science Signaling · doi:10.1126/scisignal.2000014 · Cited by 187
Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma
Pelloski, C. E., Lin, E., Zhang, L., Yung, W. K. A., Colman, H., Liu, J.-L., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2202 · Cited by 179
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Kreisl, T. N., Lassman, A. B., Mischel, P. S., Rosen, N. X., Scher, H. I., Teruya‐Feldstein, J., Shaffer, D. R., Lis, E., & Abrey, L. E. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9741-z · Cited by 183
EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Lo, H. (2010) · Current Molecular Pharmacology · doi:10.2174/1874467211003010037 · Cited by 164
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours
Halatsch, M., Schmidt, U. I., Behnke‐Mursch, J., Unterberg, A. W., & Wirtz, C. R. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.01.003 · Cited by 172
Activation of STAT3, MAPK, and AKT in Malignant Astrocytic Gliomas
Mizoguchi, M., Betensky, R. A., Batchelor, T. T., Bernay, D. C., Louis, D. N., & Nutt, C. L. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000248549.14962.b2 · Cited by 171
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Wen, P. Y., Chang, S., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not247 · Cited by 174
Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma
Leone, F., Cavalloni, G., Pignochino, Y., Sarotto, I., Ferraris, R., Piacibello, W., Venesio, T., Capussotti, L., Risio, M., & Aglietta, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1692 · Cited by 168
Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer
Schlomm, T., Kirstein, P., Iwers, L., Daniel, B., Steuber, T. P., Walz, J. C., Chun, F. K. ‐., Haese, A., Köllermann, J. W., Graefen, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1257 · Cited by 166
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP
de Vries, N. A., Buckle, T., Zhao, J., Beijnen, J. H., Schellens, J. H. M., & van Tellingen, O. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9569-1 · Cited by 161
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma
Wiencke, J. K., Zheng, S., Jelluma, N., Tihan, T., VandenBerg, S. R., Tamgüney, T., Baumber, R., Parsons, R. E., Lamborn, K. R., Berger, M. S., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-003 · Cited by 159
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Wykosky, J., Fenton, T. R., Furnari, F. B., & Cavenee, W. K. (2011) · 癌症：英文版 · doi:10.5732/cjc.010.10542 · Cited by 158
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Prasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 156
Targeting the RTK-PI3K-mTOR Axis in Malignant Glioma: Overcoming Resistance
Fan, Q.-W., & Weiss, W. A. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_67 · Cited by 155
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Sergina, N. V., & Moasser, M. M. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.10.002 · Cited by 172
Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors
Bokstein, F., Shpigel, S., & Blumenthal, D. T. (2008) · Cancer · doi:10.1002/cncr.23401 · Cited by 152
Magnetic Resonance Perfusion and Permeability Imaging in Brain Tumors
Lacerda, S., & Law, M. (2009) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2009.08.007 · Cited by 152
EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis
Talasila, K. M., Soentgerath, A., Euskirchen, P., Røsland, G. V., Wang, J., Huszthy, P. C., Prestegarden, L., Skaftnesmo, K. O., Sakariassen, P. Ø., Eskilsson, E., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1101-1 · Cited by 153
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
Gan, H. K., Burgess, A. W., Clayton, A. H. A., & Scott, A. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3898 · Cited by 147
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Hamer, P. C. D. W. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop068 · Cited by 148
Pathway inhibition: emerging molecular targets for treating glioblastoma
Wick, W., Weller, M., Weiler, M., Batchelor, T. T., Yung, A. W. K., & Platten, M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor039 · Cited by 145
Blood–brain barrier and chemotherapeutic treatment of brain tumors
de Vries, N. A., Beijnen, J. H., Boogerd, W. J., & van Tellingen, O. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.8.1199 · Cited by 142
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
Pozo, N., Zahonero, C., Fernández, P., Liñares, J. M., Ayuso‐Sacido, Á., Hagiwara, M., Pérez‐Núñez, Á., Ricoy, J. R., Hernández‐Laín, A., Sepúlveda-Sánchez, J. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63623 · Cited by 139
EGFR Activation Results in Enhanced Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase–Dependent Activation of the Sp1/Sp3 Transcription Factors in Human Gliomas
Xu, K., & Shu, H. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0141 · Cited by 139
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
Yung, W. K. A., Vredenburgh, J. J., Cloughesy, T. F., Nghiemphu, P. L., Klencke, B. J., GILBERT, M. R., Reardon, D. A., & Prados, M. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq072 · Cited by 137
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
Pinhel, I. F., MacNeill, F. A., Hills, M. J., Salter, J., DETRE, S. I., A’Hern, R., Nerurkar, A. Y., Osin, P., Smith, I. E., & Dowsett, M. (2010) · Breast Cancer Research · doi:10.1186/bcr2719 · Cited by 137
MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
Cheng, Y., Zhang, Y., Zhang, L., Ren, X., Huber-Keener, K. J., Liu, X., Zhou, L., Liao, J., Keihack, H., Li, Y., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0606 · Cited by 135
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Brandes, A. A., Franceschi, E., Tosoni, A., Hegi, M. E., & Stupp, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1810 · Cited by 135
Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding
Sami, A., & Karsy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0800-5 · Cited by 137
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging
Liu, X., Ide, J. L., Norton, I. H., Marchionni, M. A., Ebling, M. C., Wang, L. Y., Davis, E., Sauvageot, C., Kesari, S., Kellersberger, K. A., et al. (2013) · Scientific Reports · doi:10.1038/srep02859 · Cited by 133
New treatment strategies for malignant gliomas
Sathornsumetee, S., & Rich, J. N. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1087 · Cited by 132
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
Reardon, D. A., Groves, M. D., Wen, P. Y., Nabors, B., Mikkelsen, T., Rosenfeld, S., Raizer, J. J., Barriuso, J., McLendon, R. E., Suttle, A. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1707 · Cited by 131
High-resolution Global Genomic Survey of 178 Gliomas Reveals Novel Regions of Copy Number Alteration and Allelic Imbalances
Kotliarov, Y., Steed, M. E., Christopher, N., Walling, J., Su, Q., Heiss, J. D., Rosenblum, M., Mikkelsen, T., Zenklusen, J. C., & Fine, H. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1691 · Cited by 127
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Mellinghoff, I. K., Cloughesy, T. F., & Mischel, P. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1992 · Cited by 130
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors
Lauko, A. J., Lo, A., Ahluwalia, M. S., & Lathia, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.014 · Cited by 132
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma
Narsinh, K. H., Perez, E., Haddad, A. F., Young, J. S., Savastano, L. E., Villanueva-Meyer, J. E., Winkler, E. A., & de Groot, J. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01338-x · Cited by 140
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition
Torbett, N., Luna-Moran, A., Knight, Z. A., Houk, A., Moasser, M., Weiss, W., Shokat, K., & Stokoe, D. (2008) · Biochemical Journal · doi:10.1042/bj20080639 · Cited by 138
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy
Gong, X. W., Schwartz, P. H., Linskey, M. E., & Bota, D. A. (2011) · Neurology · doi:10.1212/wnl.0b013e318212a89f · Cited by 120
PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges
Cheng, C. K., Fan, Q., & Weiss, W. A. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00233.x · Cited by 125
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Karpel‐Massler, G., Schmidt, U. I., Unterberg, A. W., & Halatsch, M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0479 · Cited by 120

Authors: Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., Berger, M. S., & Stokoe, D.
Affiliations: University of California, San Francisco (US)
Corresponding author: Haas-Kogan, Daphne A.
ORCID: Haas-Kogan, Daphne A.
Prados, Michael D.
Jelluma, Nannette
Arvold, Nils D.
Baumber, Rachel
Berger, Mitchel S.
Stokoe, David
Venue: JNCI Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2005-06-15
Volume: 97
Issue: 12
Pages: 880-887
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/dji161
OpenAlex: W2104743043
Cited by: 465
References: 37
Citations by year: 2026: 3 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 13 · 2016: 6 · 2015: 17 · 2014: 24 · 2013: 27 · 2012: 34
FWCI: 22.18
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5m01rr000079-42)
National Cancer Institute (P50CA097257)
National Institute of Neurological Disorders and Stroke (P01NS042927, P01 NS42927)
National Center for Research Resources (M01 RR-00079)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: erlotinib, EGFR tyrosine kinase inhibitors, high-grade glioma, glioblastoma, EGFR amplification, EGFRvIII, Akt phosphorylation, Akt, temozolomide, predictive biomarkers, treatment response, PTEN mutation, time to progression
MeSH terms: Erlotinib Hydrochloride, Temozolomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Drug Administration Schedule, Female, Glioma, Humans, Immunohistochemistry, Male, Middle Aged, Mutation, Phosphoric Monoester Hydrolases, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Supratentorial Neoplasms, Protein Serine-Threonine Kinases, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Area Under Curve, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks